WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526686
CAS#: 1429639-50-8
Description: CZ415 is a potent ATP-competitive mTOR inhibitor with unprecedented selectivity over any other kinase (IC50 = 14.5 nM IC50 for pS6RP and 14.8 nM for pAKT) with very good cell permeability (Kd app = 6.9 nM). Pharmacokinetic properties of moderate clearance and good oral bioavailability showed suitability of CZ415 for progression to in vivo studies. CZ415 represents an ideal molecule for the pharmacological investigation of mTOR pathophysiological role in vivo.
Hodoodo Cat#: H526686
Name: CZ415
CAS#: 1429639-50-8
Chemical Formula: C22H29N5O4S
Exact Mass: 459.19
Molecular Weight: 459.565
Elemental Analysis: C, 57.50; H, 6.36; N, 15.24; O, 13.93; S, 6.98
Synonym: CZ415; CZ-415; CZ 415.
IUPAC/Chemical Name: (S)-1-(4-(7,7-dimethyl-4-(3-methylmorpholino)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)phenyl)-3-ethylurea
InChi Key: IZLPVLBNRGPOHA-AWEZNQCLSA-N
InChi Code: InChI=1S/C22H29N5O4S/c1-5-23-21(28)24-16-8-6-15(7-9-16)19-25-18-17(13-32(29,30)22(18,3)4)20(26-19)27-10-11-31-12-14(27)2/h6-9,14H,5,10-13H2,1-4H3,(H2,23,24,28)/t14-/m0/s1
SMILES Code: O=C(NCC)NC1=CC=C(C2=NC(N3[C@@H](C)COCC3)=C4C(C(C)(C)S(C4)(=O)=O)=N2)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. |
In vitro activity: | Results showed that CZ415 inhibited CC cell survival in a dose- and time-dependent manner, and 100 nanomolar and 48 h were the optimal conditions. Reference: Reprod Sci. 2021 Feb;28(2):524-531. https://pubmed.ncbi.nlm.nih.gov/32944878/ |
In vivo activity: | In vivo studies revealed that oral administration of CZ415 significantly suppressed HepG2 xenograft tumor growth in severe combined immuno-deficient (SCID) mice. Activation of mTORC1/2 was also largely inhibited in CZ415-treated HepG2 tumor tissue. Reference: Biochem Biophys Res Commun. 2017 Jun 3;487(3):494-499. https://pubmed.ncbi.nlm.nih.gov/28366631/ |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 73.7 | 160.30 | |
DMSO:PBS (pH 7.2) (1:6) | 0.1 | 0.22 | |
DMF | 30.0 | 65.28 | |
Ethanol | 10.0 | 21.76 |
The following data is based on the product molecular weight 459.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | 1. Zhang J. Targeting mTOR by CZ415 Suppresses Cell Proliferation and Promotes Apoptosis via Lipin-1 in Cervical Cancer In Vitro and In Vivo. Reprod Sci. 2021 Feb;28(2):524-531. doi: 10.1007/s43032-020-00313-4. Epub 2020 Sep 17. PMID: 32944878. 2. Li X, Li Z, Song Y, Liu W, Liu Z. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth. Cell Physiol Biochem. 2018;46(2):579-590. doi: 10.1159/000488625. Epub 2018 Mar 28. PMID: 29617677. 3. Xie J, Li Q, Ding X, Gao Y. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells. Cell Physiol Biochem. 2018;46(2):676-686. doi: 10.1159/000488724. Epub 2018 Mar 29. PMID: 29621758. 4. Zhang W, Chen B, Zhang Y, Li K, Hao K, Jiang L, Wang Y, Mou X, Xu X, Wang Z. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415. Biochem Biophys Res Commun. 2017 Jun 3;487(3):494-499. doi: 10.1016/j.bbrc.2017.03.156. Epub 2017 Mar 30. PMID: 28366631. |
In vitro protocol: | 1. Zhang J. Targeting mTOR by CZ415 Suppresses Cell Proliferation and Promotes Apoptosis via Lipin-1 in Cervical Cancer In Vitro and In Vivo. Reprod Sci. 2021 Feb;28(2):524-531. doi: 10.1007/s43032-020-00313-4. Epub 2020 Sep 17. PMID: 32944878. 2. Li X, Li Z, Song Y, Liu W, Liu Z. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth. Cell Physiol Biochem. 2018;46(2):579-590. doi: 10.1159/000488625. Epub 2018 Mar 28. PMID: 29617677. |
In vivo protocol: | 1. Xie J, Li Q, Ding X, Gao Y. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells. Cell Physiol Biochem. 2018;46(2):676-686. doi: 10.1159/000488724. Epub 2018 Mar 29. PMID: 29621758. 2. Zhang W, Chen B, Zhang Y, Li K, Hao K, Jiang L, Wang Y, Mou X, Xu X, Wang Z. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415. Biochem Biophys Res Commun. 2017 Jun 3;487(3):494-499. doi: 10.1016/j.bbrc.2017.03.156. Epub 2017 Mar 30. PMID: 28366631. |
1: Cansfield AD, Ladduwahetty T, Sunose M, Ellard K, Lynch R, Newton AL, Lewis A,
Bennett G, Zinn N, Thomson DW, Rüger AJ, Feutrill JT, Rausch O, Watt AP,
Bergamini G. CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in
a Collagen Induced Arthritis Model. ACS Med Chem Lett. 2016 Jun 10;7(8):768-73.
doi: 10.1021/acsmedchemlett.6b00149. PubMed PMID: 27563401; PubMed Central PMCID:
PMC4983736.